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Abstract Interleukin 1 (IL-1) delivers a stimulatory signal
which increases the expression of a set of genes by modulating
the transcription factor NF-UB. The IL-1 receptors are
transmembrane glycoproteins which lack a catalytic domain.
The C-terminal portion of the type I IL-1 receptor (IL-1RI) is
essential for IL-1 signalling and for IL-1 dependent activation of
NF-UB. This portion contains a putative phosphatidylinositol
3-kinase (PI 3-kinase) binding domain (Tyr-E-X-Met), which is
highly conserved between the human, mouse and chicken
sequences, as well as the related cytoplasmic domain of the
Drosophila receptor Toll. This observation prompted us to
investigate the role of PI 3-kinase in IL-1 signalling. Here we
report evidence that PI 3-kinase is recruited by the activated
IL-1RI, causing rapid and transient activation of PI 3-kinase.
We also show that the receptor is tyrosine phosphorylated in
response to IL-1. Expression of a receptor mutant lacking the
putative binding site for p85 demonstrates that Tyr479 in the
receptor cytoplasmic domain is essential for PI 3-kinase
activation by IL-1. Our results indicate that PI 3-kinase is
likely to be an important mediator of some IL-1 effects,
providing docking sites for additional signalling molecules.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Interleukin 1 (IL-1) constitutes a family of polypeptide cy-
tokines secreted in response to in£ammatory and immunolog-
ical diseases and exhibiting a wide range of biological activ-
ities [11]. The most consistent property of IL-1 is to up-
regulate the expression of a set of genes through the modula-
tion of the transcription factors NF-UB and AP-1. Although
the biological e¡ects of IL-1 are well documented, the molec-
ular mechanism of signalling by IL-1 is complex. IL-1 binds to
transmembrane glycoprotein receptors which lack a catalytic
domain [8,40], and are therefore supposed to interact with
accessory signalling components. Two receptor proteins have
been identi¢ed so far, type I and type II IL-1 receptors (IL-
1Rs). The 80-kDa IL-1RI possesses a 200 amino acid cyto-
plasmic tail critical for IL-1 signalling; conversely, the 68-kDa
type II IL-1R lacks this cytoplasmic tail almost completely,
and it appears to act as a decoy receptor. While both receptor
types are coexpressed on many cell types, they appear to be
functionally independent and do not bind IL-1 as a hetero-
dimer complex. Cloning and sequencing of the IL-1 receptors
provided very few clues as to what the post-receptor events
may be [40]. It is clear, however, that IL-1 is a pleiotropic
molecule, able to generate a number of signals through more
than one signalling pathway. Consequently, a wide variety of
post-receptor events have been reported, which include gen-
eration of second messengers, such as cyclic AMP and ceram-
ide [23], as well as activation of protein kinase C and G-pro-
teins [11]. However, these e¡ects are often almost anecdotal,
being cell-type dependent, and their physiological signi¢cance
for signalling by IL-1 remains to be established.
Deletion of most of the cytoplasmic region of the murine
IL-1R does not a¡ect the binding of IL-1 to the receptor, and
still allows internalisation and nuclear localisation of IL-1
[17]. Furthermore, mutant IL-1R genes carrying di¡erent de-
grees of truncations in the cytoplasmic COOH-terminal
[7,26,36] have allowed the identi¢cation of a domain, between
amino acids 486^527, required by IL-1 to activate NF-UB.
Much e¡ort has been focused in this direction, in considera-
tion of the fact that most of the well known biological e¡ects
of IL-1 are mediated by NF-UB transcriptional activity
[33,39]. In fact, many cytokines activate the transcription fac-
tor NF-UB through hitherto unrelated signalling pathways.
Recently, the cloning and characterisation of a second subunit
of the IL-1 receptor, the IL-1 receptor accessory protein
(IL-1RAcP), associating with IL-1RI, has been reported
[16]. IL-1RAcP increases the binding a⁄nity of IL-1RI
when the two are coexpressed [16], and it plays an important
role in IL-1 signalling restoring IL-1 induced responses in an
IL-1 non-responsive cell line expressing IL-1RI, but lacking
constitutive IL-1RAcP [24,25,43,44]. IL-1 stimulation evokes
the aggregation of the IL-1RI with the accessory protein,
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which in turn associates with the serine/threonine kinase
IRAK. IRAK is therefore recruited to the activated IL-1RI
[5,20], together with the adaptor protein TRAF6 [6]. How-
ever, neither TRAF6 nor IL-1RI/AcP are substrates of
IRAK. A dominant-negative mutant of TRAF6 blocks IL-1
dependent activation of NF-UB [6], resembling another mem-
ber of the TRAF family, TRAF2, which is required for NF-
UB activation through the TNF receptors. TRAF6, as well as
TRAF2, interacts with the NF-UB-inducing kinase NIK
[6,29], leading to activation of NF-UB. At this point, signals
from entirely unrelated receptors converge, hinting at a path-
way common to cytokine receptors belonging to di¡erent fam-
ilies. Another unifying phenomenon connecting the signalling
mechanism of the IL-1RI to other cytokine receptors has been
the recent identi¢cation of a STAT-like factor activated by
IL-1, LPS and IL-6, able to bind to GAS-like sequences with-
in the IL-1B gene [42]. The STAT pathway signals directly to
the nucleus, thus providing a direct connection with the tran-
scriptional machinery. The STAT-like protein is phosphory-
lated on tyrosine and this phosphorylation is essential for
DNA binding. Canonical STAT proteins are known to be
activated through phosphorylation by Jak tyrosine kinases
which, upon ligand binding, associate with the cytoplasmic
domain of the activated receptor. Therefore, a STAT-like pro-
tein would require the presence of a tyrosine kinase activated
by IL-1 and possibly associating to the receptor. However,
tyrosine phosphorylation of the receptor has not been dem-
onstrated yet, although an increase in the phosphotyrosine
pro¢le of cells treated with IL-1 has been observed. Several
laboratories have recently demonstrated that phosphatidylino-
sitol 3-kinase (PI 3-kinase) is a target for a variety of cell
surface receptors [4], including cytokine receptors [35]. The
identi¢cation, within the cytoplasmic domain of the IL-1RI,
of the putative binding site for PI 3-kinase (Tyr-X-X-Met)
prompted us to investigate whether PI 3-kinase is part of
the signalling mechanism of IL-1.
In this article, we present evidence that PI 3-kinase is re-
cruited and activated by IL-1RI through binding of the SH2
domains to the consensus sequence on the C-terminal tail of
the receptor, and that Tyr479 in the IL-1 receptor is essential
for PI 3-kinase activation.
2. Materials and methods
2.1. Materials
All cell culture products were from Flow. Radiochemicals, nitro-
cellulose membrane and ECL reagents were from Amersham. Pro-
tease inhibitors were from Calbiochem, Protein A-Sepharose CL-4B
was from Pharmacia LKB. Anti-P-tyrosine (clone 4G10) and anti-p85
(06-195) were from UBI. Anti-IL-1 type I receptor (C-20) was from
Santa Cruz (sc-687). Protein concentration was determined with a
Bradford protein assay kit (Bio-Rad). All other products were from
Sigma, unless speci¢ed otherwise.
2.2. Cell culture
Saos2 cells were obtained from the American Type Culture Collec-
tion and were cultured as described previously [30,37]. For experi-
ments requiring growth factor-deprived cells, sub-con£uent cells
were maintained 48 h in serum-free medium, in the presence of
0.5% BSA, then cells were treated with IL-1L (2 ng/ml) for the indi-
cated times.
2.3. Plasmid constructs
The wild-type human IL-1 type I expression vector (CNOD-IL-1R)
was the kind gift of Peter R. Young (SmithKline Beecham, King of
Prussia, PA, USA). Mutations were introduced by using recombinant
polymerase chain reaction synthesis employing primers that contained
a single base-pair mismatch [18]. Mutation speci¢c primers were either
24 or 25 bp long and contained a single mismatch at a central position
in which a TAT codon was changed to TTT for Y479F and a TAC
was changed to a TTC for Y519F. Flanking primers contained up-
stream and downstream EcoRI restriction sites to permit cloning into
an appropriately digested wild-type CNOD-IL-1R vector. The num-
bering convention used for the IL-1RI protein corresponds to that of
the 552 amino acid mature protein which does not contain the
17 amino acid secretory signal [12].
2.4. Transfections and CAT assay
Stable clones carrying either WT, Y479F or Y519F receptors were
obtained transfecting Saos2 cells that had been plated at 50% con£u-
ency the day before, using 10 Wg of the expression vectors described
above. Forty-eight hours after transfection, transformants were se-
lected in medium containing the neomycin analog G418 (Sigma, St.
Louis, MO, USA) at a concentration of 500 Wg/ml. Clones were har-
vested and expanded separately 40 days in the presence of G418.
Receptor expression was analysed by Western blotting.
For transient transfections, cells were grown in 175-cm2 £asks to
70% con£uence, then transfections were performed with the calcium-
phosphate coprecipitation technique [1] in 10% FCS for 5 h. After
transfection, cells were serum starved for 48 h and then treated with
IL-1 (2 ng/ml). Total amount of DNA was kept constant by using
empty vectors, and results were normalised to the level of L-galacto-
sidase activity as described [1,2].
For CAT assay, cells were transfected with a reporter plasmid car-
rying four rel repeats upstream of the CAT gene [28]. After 48 h in
serum-free medium, cells were treated for 6 h with 2 ng/ml of IL-1 and
50 Wg of protein extracts, prepared in TEN solution (40 mM Tris-
HCl, pH 7.5, 1 mM EDTA, 150 mM NaCl) with the freeze-thaw
method [1], were assayed. The acetylated and non-acetylated forms
of [14C]chloramphenicol were separated by thin layer chromatography
(TLC). Data is presented as percentage of acetylation and is the aver-
age of at least four independent transfection experiments, quanti¢ed
using a Bio-Rad Molecular Imager.
2.5. Immunoprecipitation
To assay for PI 3-kinase activity, cell monolayers were washed
twice with cold phosphate-bu¡ered saline (PBS) and lysed directly
in IP bu¡er (20 mM HEPES, pH 7.5, 1% NP-40, 50 mM NaF,
100 mM NaCl, 1 mM Na3VO4, 0.5 mM PMSF, 10 Wg/ml leupeptin,
10 Wg/ml aprotinin, 10 Wg/ml pepstatin, 5 Wg/ml calpain inhibitors),
then cleared at 7000Ug in microfuge for 15 min at 4‡C. Lysates were
precleared by centrifugation and then immunoprecipitation was car-
ried out incubating 1 mg lysates with anti-P-tyr (5 Wg), anti-IL-1RI
(2.5 Wg) or anti-p85 (1 Wl) antibodies for 2 h at 4‡C with constant
agitation, followed by 1 h incubation with 50 Wl of Protein A-Sephar-
ose (10% w/v). Pellets were washed three times in PBS containing 1%
NP-40, twice in 0.1 M Tris, 0.5 M LiCl and twice in TNE. All bu¡ers
contained 100 WM Na3VO4. Pellets, resuspended in 50 mM HEPES,
pH 7.5, 25 mM MgCl2, were preincubated at room temperature (r.t.)
for 10 min with PI vesicles (10 Wg/sample), then [Q-32P]ATP was added
(10 WCi/sample) and pellets were further incubated at r.t. for 20 min.
The reaction was stopped with 1 M HCl and methanol/chloroform
(1:1). The organic phase was resolved on oxalate-coated TLC silica
plates (Silica Gel 60, Merck) and the results quanti¢ed using a Bio-
Rad GS-250 Molecular Imager.
2.6. Binding assay
Cells were lysed in IP bu¡er as described above. Lysates of unsti-
mulated and IL-1 stimulated cells were boiled in 1% SDS, diluted
10 times with lysis bu¡er, and incubated for 2 h at 4‡C with 2.5 Wg
of the p85 C-terminal or N-terminal SH2-GST fusion protein conju-
gated with agarose beads (UBI), with constant agitation. Beads were
washed as described for immunoprecipitation procedures, resuspended
in 30 Wl of 2U Laemmli’s bu¡er containing 10 mM glutathione and
boiled for 10 min at 100‡C. Pellets were then separated by centrifu-
gation and proteins resolved by 7.5% SDS-PAGE, transferred to ni-
trocellulose ¢lter and revealed using anti-p85 or anti-pTyr antibody
(4G10). In some experiments, the ¢lters were stripped by exposing
them to 62.5 mM Tris (pH 6.8), 0.1 M L-mercaptoethanol, 2% SDS
at 50‡C for 30 min. Filters were then reprobed with di¡erent anti-
bodies as described.
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3. Results
3.1. Association of p85 with the activated IL-1 receptor
Initial studies of the biochemical basis of responses to IL-1
have been hampered by the low number of receptors, which
renders their detection by conventional immunochemical tech-
niques very di⁄cult. To increase the number of IL-1RI, Saos2
cells were stably transfected with a plasmid containing the full
length human cDNA for type I receptor (Saos2/IL-1RI).
The IL-1RI can be easily immunoprecipitated from Saos2/
IL-1RI (Fig. 1A). Conversely, from cells which do not over-
express IL-1RI, the band corresponding to the receptor is
undetectable. In the transfected cells, the receptor is detected
as a doublet representing both the non-glycosylated 60-kDa
and the larger, 80-kDa glycosylated forms [12].
IL-1 treatment of Saos2/IL-1RI cells led to a very rapid
increase of PI 3-kinase activity, as detected by immune-com-
plex kinase assay using anti-IL-1RI as the immunoprecipitat-
ing antibody (Fig. 1B). The time course of IL-1-dependent PI-
3 kinase activity in IP from Saos2 cells was compared using
anti-p85, anti-IL-1R and anti-P-Tyr antibodies. In all cases
the activity was near maximal between 2 and 5 min. Further-
more, the relative increase in PI 3-kinase activity in the anti-
IL-1R IP was similar to the relative increase observed in the
anti-P-Tyr IP. A sustained PI 3-kinase activity was main-
tained for at least 30 min after exposure to IL-1. In untrans-
fected Saos2 cells, the e¡ect of IL-1 stimulation on PI 3-kinase
activity is less pronounced, although still detectable. The e¡ect
was observed at a physiological dose of IL-1 (2 ng/ml), and
doses up to 100-fold higher than this did not signi¢cantly
modify this response (not shown).
IL-1R and p85 coprecipitate from lysates of Saos2/IL-1RI
cells stimulated with IL-1, using the 4G10 anti-phosphotyro-
sine or anti-receptor antibodies, as shown in Fig. 2A. The
amount of p85 recruited by IL-1R, as detected by immuno-
precipitation with the anti-receptor antibody, was already de-
tectable 2 min after stimulation with IL-1, and increased at
5 min. p85 was also detectable, with the same time course, in
anti-phosphotyrosine immunoprecipitates, showing the associ-
ation of p85 with some tyrosyl-phosphorylated protein com-
plex. The IL-1 induced association of PI 3-kinase with the
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Fig. 2. A: IL-1 stimulates the association of PI 3-kinase with the
IL-1R. Serum-starved Saos2/IL-1R cells were untreated (lanes 1, 4)
or treated with IL-1 (2 ng/ml) for 2 (lanes 2, 5) or 5 (lanes 3, 6)
min. Cleared lysates (1 mg) were immunoprecipitated with anti-P-
Tyr (5 Wg) (lanes 1, 2, 3), anti-IL-1R (2.5 Wg) (lanes 4, 5, 6), or
anti-p85 (1 Wl) (lane 7). Then proteins were resolved by SDS-PAGE
(7.5%), transferred to nitrocellulose and probed with anti-p85 anti-
body (1:3000). B: IL-1R is tyrosine phosphorylated in response to
IL-1. Lysates were immunoprecipitated with anti-IL-1R (2.5 Wg),
and nitrocellulose was probed with anti-phosphotyrosine antibody
(clone 4G10, UBI) (1:1000), or anti-IL-1R (1:750), as indicated.
Fig. 1. IL-1 activates PI 3-kinase in Saos2/IL-1RI cells. A: Saos2
cells were stably transfected with wild-type IL-1RI expression vector
(Saos2/IL-1R), or untransfected (Saos2) and 500 Wg of cell lysate
were immunoprecipitated with 2.5 Wg of anti-IL-1RI (C-terminal,
Santa Cruz). B: Serum-starved Saos2 or Saos2/IL-1R cells were ei-
ther left untreated (time 0) or were treated with IL-1 (2 ng/ml) for
the indicated times. PI 3-kinase activity was immunoprecipitated
from 1 mg of Saos2/IL-1R cleared lysates using anti-IL-1R, 2.5 Wg,
or anti-Tyr(P), 5 Wg antibodies, and from Saos2 using anti-p85 (1 Wl)
antibody, and assayed using exogenous PtdIns as a substrate. n = 3
experiments.
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activated IL-1R most likely occurs through an interaction
between the SH2 domains of p85 and either one or more
phosphorylated tyrosines within the IL-1R cytoplasmic tail
or a phosphorylated protein intermediate. Here we show
that the receptor can be rapidly Tyr-phosphorylated in re-
sponse to IL-1 (Fig. 2B), thus creating binding sites for p85
SH2 domains. The association of the phosphorylated receptor
with p85 could be direct or indirect. To test for direct binding,
we utilised the fact that SH2 domains recognise linear phos-
phopeptide sequences that persist after the three-dimensional
structure of the proteins has been disrupted by denaturation
[27]. Therefore, lysates from Saos2/IL-1RI cells were boiled in
1% SDS, diluted 10 times in lysis bu¡er, then incubated with
the immobilised p85 C-terminal and N-terminal SH2 domains
GST fusion proteins. Although with slightly di¡erent a⁄nity,
both domains were able to associate with the receptor in de-
naturing conditions, thus showing that the interaction is di-
rect, in an IL-1 dependent manner (Fig. 3). The data reported
so far show that IL-1 stimulates PI 3-kinase activity, and that
the activated IL-1 receptor recruits PI 3-kinase, presumably
through the formation of a phosphotyrosyl complex with p85-
SH2 domains, as suggested by in vitro binding data. The
precise mapping of the p85 binding site on the IL-1 receptor,
however, requires the expression of receptor mutants lacking
the motif predicted to bind this domain. For this purpose, the
Y479F receptor mutant, which contains a Tyr to Phe point
mutation in the IL-1 receptor p85 consensus sequence, and the
Y519F mutant, containing a Tyr to Phe mutation at an irrel-
evant position, were generated. The wild-type and mutant
receptors were expressed in Saos2 cells, and cells were stimu-
lated with IL-1. While cells expressing the wild-type or the
Y519F mutated receptors retained their ability to induce acti-
vation of PI 3-kinase in response to IL-1, expression of the
Y479F receptor mutant completely prevented this activation
(Fig. 4A). Moreover, we assayed the IL-1-induced association
of p85 with IL-1RI in cells expressing the Y479F receptor.
IL-1 treatment of these cells yielded no detectable p85 copre-
cipitated with the receptor (Fig. 4C), clearly indicating
that Tyr479 is required for p85 recruitment by the activated
IL-1RI.
3.2. Induction of transcriptional activation
IL-1 can induce speci¢c genes through the transcription
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Fig. 4. E¡ect of receptor mutants on PI 3-kinase activity and associ-
ation. Human Saos2 cells were transiently transfected with wild-type
(WT), mutant Tyr519Phe or Tyr479Phe IL-1RI expression vectors.
Then, cells were serum-starved for 48 h and treated with IL-1 (2 ng/
ml) for 5 min. Cleared lysates immunoprecipitated with anti-IL-1R
antibody were split and used for PI 3-kinase activity (A), Western
blotting with anti-IL-1R (B), or anti-p85 (C).
Fig. 3. Association of IL-1RI with GST-SH2 domains. Serum-
starved Saos2/IL-1R cells were untreated or treated with IL-1 (2 ng/
ml), as indicated. Cleared lysates were boiled in 1% SDS, diluted
10 times in lysis bu¡er and incubated with 5 Wg of the C-terminal
or the N-terminal GST-SH2 fusion proteins, conjugated with agar-
ose beads. Pellets were boiled in Laemmli bu¡er plus 10 mM gluta-
thione, subjected to SDS-PAGE and immunoblotted using anti-IL-
1RI antibody (1:750 dilution).
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factor NF-UB [33,39], suggesting that complex, cell-speci¢c
molecular mechanisms operate to transduce a signal from
the activated IL-1 receptor to the nucleus.
We performed transient transfection experiments using a
UB-CAT reporter plasmid, carrying four rel repeats in front
of the CAT cDNA, which had been previously shown to
respond speci¢cally to NF-UB activation [28]. Expression of
UB-CAT in Saos2/IL-1R leads to an IL-1-dependent increase
in the transcriptional activation of NF-UB. Similar results
were obtained with the Tyr519 receptor mutant. However, ex-
pression of the UB-CAT reporter in cells carrying the Tyr479
mutant failed to enhance transactivation signi¢cantly (Fig. 5).
This data shows that the Tyr479 residue is important to trigger
NF-UB transcriptional activity by IL-1, and suggests an in-
volvement of PI 3-kinase in this pathway. However, since the
use of receptor mutants may a¡ect signalling pathways other
than one mediated by PI 3-kinase, the role of PI 3-kinase in
IL-1-mediated induction of NF-UB transcriptional activity
was investigated by co-expression of the UB-CAT reporter
with a constitutively active form of p110 (p110*) [19] in
Saos2 cells. Expression of p110* with UB-CAT in serum-
starved Saos2 cells resulted in a striking induction of CAT
activity in the absence of stimulus, and stimulation of CAT
activity was completely independent of the receptor type (Fig.
5). Activation of CAT by p110* expression was further en-
hanced by IL-1 treatment; conversely, in Saos2 cells express-
ing a kinase dead mutant p110 (p110v kin) [19], basal CAT
activity was extremely low and the response to IL-1 was al-
most completely lost, con¢rming speci¢city.
It has been recently demonstrated that the transactivation
domain of the p65 subunit undergoes phosphorylation [32,38].
Although the precise function of this phosphorylation is still
unclear, it features a further checkpoint in the regulation of
NF-UB transcriptional activity, which may be under control of
the IL-1 stimulated PI 3-kinase pathway. Alternatively, the
target of PI 3-kinase could be a di¡erent member of the
NF-UB transcriptional complex, which can interact with
NF-UB in a DNA-independent manner, rather than NF-UB
itself [3,13,41].
4. Discussion
Intracellular events linking the activation of IL-1 receptors
to speci¢c cellular responses are unclear. IL-1 activates the
transcription factors NF-UB and AP-1 within minutes, trans-
mitting a signal from the cell surface receptor to the nucleus.
Depending on the nature of the target cell, IL-1 can elicit
proliferative, di¡erentiative, or metabolic responses [11].
How the speci¢city of each e¡ect is controlled, is poorly
understood. One level of control may lie in the speci¢city of
the receptor-signalling complex formation. A number of com-
ponents of the IL-1 receptor complex have recently emerged:
activation of IL-1R induces association of the receptor with
an accessory membrane-spanning protein, the IL-1RAcP, es-
sential for full activation [16]. The activated IL-1RAcP com-
plex recruits the serine/threonine kinase IRAK, through bind-
ing to the AcP cytoplasmic tail [20], and the adaptor protein
TRAF6 [6]. The activated complex signals to a downstream
kinase, NIK, which in turn induces the phosphorylation of I-
UB by the I-UB kinase IKK-K [10,21,37], followed by NF-UB
activation. Therefore, NIK activation by the TRAFs repre-
sents the point at which signals from IL-1 and TNF, although
triggered by entirely unrelated receptors, converge. PI 3-kinase
has been implicated recently in signal transduction from
some cytokine receptors, such as the IL-2, IL-4, IL-7 and,
more recently, IL-1 receptor [22,38,35]. In the case of IL-1,
IL-2 and IL-4, recruitment of PI 3-kinase by the receptor was
reported [38]. The observation that the IL-1RI cytoplasmic
domain possesses a PI 3-kinase consensus sequence suggests
involvement of PI 3-kinase in IL-1 signalling. Remarkably,
the Y-E-X-M motif is highly conserved between human,
mouse, chicken and Drosophila Toll [15]. It is worth mention-
ing that the IL-1R accessory protein [16], as well as MyD88
[31], contain a putative binding site for PI 3-kinase, analogous
to the binding site on the erythropoietin receptor [9], which
may represent a second binding site for p85. Here, we present
evidence that PI 3-kinase is recruited by the activated, Tyr-
phosphorylated IL-1R, as shown by coprecipitation experi-
ments (Fig. 2). Furthermore, PI 3-kinase is rapidly and tran-
siently activated following IL-1 treatment (Fig. 1). Binding
experiments with recombinant GST fusion proteins containing
the C- and N-terminal SH2 domains of p85 show that both
domains are able to bind the activated IL-1 receptor in vitro
(Fig. 3). Taken together, these data indicate that PI 3-kinase is
recruited to the activated IL-1 receptor through binding of the
SH2 domains of p85 to the C-terminal tail of the receptor.
Our observations using receptors with a Tyr to Phe mutation
in the putative PI 3-kinase binding domain clearly demon-
strate that Tyr479 is essential for IL-1 induced PI 3-kinase
activation and receptor association (Fig. 4). It is tempting to
speculate about the physiological function of the IL-1 induced
PI 3-kinase pathway in cellular responses to IL-1. The 3P-
phosphoinositides have been shown to activate a growing
number of kinases by binding to speci¢c protein modules
[34,14]. These kinases are therefore possible candidates as reg-
ulators of the multiple transcriptional e¡ects driven by IL-1.
Indeed, it is worth remembering that phosphorylation of NF-
UB is required to trigger the response to the inducer [32], and
it has been demonstrated that the activity of NF-UB can be
modulated by phosphorylation of its active nuclear form at
both p65 transactivation domains [38].
Furthermore, we demonstrate that activated PI 3-kinase
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Fig. 5. E¡ect of IL-1 and activated PI 3-kinase on gene expression.
Cells were co-transfected with a 4U NF-UB-CAT reporter plasmid
and the di¡erent expression vectors indicated in the ¢gure (10 Wg
each), plus 4 Wg of the L-galactosidase vector pCH110 (Pharmacia
Biotech); the amount of total DNA was kept constant by using
empty vectors. Where indicated, 48-h serum-starved cells were
stimulated for 6 h with IL-1 (2 ng/ml) before extraction for CAT
assay. Results represent ¢ve di¡erent transfections, and are normal-
ised to the L-galactosidase activity present in the extracts.
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(p110*) induces NF-UB transactivation in the absence of stim-
uli, and that Tyr479, in the PI 3-kinase binding site, is impor-
tant for NF-UB transcriptional activity; coexpression of a UB-
CAT reporter and the mutated receptors leads to a loss of IL-
1 dependent CAT activity only in cells carrying the Tyr479Phe
receptor (Fig. 5). This strongly suggests that PI 3-kinase is
involved in triggering this event by IL-1. The data obtained
in our system suggest that expression of the Tyr479Phe mutant
impairs receptor-associated signals and blocks transcriptional
activity preventing either the phosphorylation of NF-UB sub-
unit or the activation of some distal factor interacting with
NF-UB. Moreover, given its multifunctional structure, p85
association with the activated IL-1 receptor may serve as a
platform for recruitment of additional proteins and this path-
way, in combination with the known components of the IL-1
receptor complex, which depends upon a distinct part of the
IL-1RI cytoplasmic domain, may generate the well known
complexity of IL-1 biological functions. Despite many open
questions, the identi¢cation of PI 3-kinase as a member of the
IL-1 signalling pathway in Saos2 cells represents an important
step towards a better understanding of the pleiotropic biolog-
ical e¡ects evoked by IL-1.
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